Erazo Valle-Solís AA, Bautista-Santos A, Calderillo-Ruiz G, Campos-Gómez S, Cervantes-Sánchez G, Cortes-Cárdenas S, Chávez-Hernández N, de Anda-González J, Dip-Borunda K, García-Briseño L, Flores-Zorrilla C, González-Huezo S, González-Vela J, Huitzil-Fidel D, Mariscal-Ramírez I, Mora-Pérez J, Orozco-Vázquez J, Pérez-Zincer F, Pimentel-Rentería A, Quintana-Quintana M, Suárez-Sahui T, Torrecillas-Torres L, Padilla-Rosciano A, López-Basave H

Language: Spanish
References: 71
Page: 41-50
PDF size: 148.62 Kb.

ABSTRACT

Introduction: The hepatocarcinoma (HCC) is a type of tumor that usually presents unfavorable prognosis. In the last decade important advances has been presented, about the staging, diagnostic and treatment, that have modified the patient´s life expectancy. Objetive: To describe and analize the existence evidence about the HCC epidemiology, diagnostic and treatment in Mexican population. Material and method: A meeting of medics from different specialties and widely experience in the management of HCC was convened, whom provided current information on the treatment and diagnosis of this pathology, in order to generate a guide for the orientation and management of this disease. The exposed recommendations in this review have been confirmed and evaluated through the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system. Results: To achieve an impact in global and progression-free survival, patients with HCC should receive multidisciplinary treatment, from the early to the locally advanced stage. Sorafenib use is indicated in patients in locally advanced stage Child-Pugh A. Conclusion: The diagnosis and treatment of HCC should be individualized according to what is shown in this document and should be trans-disciplinaries; the patient must be classified according to the Barcelona Clinic Liver Cancer scale, as well as determine their score in the Eastern Cooperative Oncology Group and Child-Pugh scales to achieve an impact on global survival.

REFERENCES

1. Oñate-Ocaña L, Ochoa F. Sistema GRADE para clasificar nivel de evidencia y grado de las recomendaciones para la elaboración de guías de buena práctica clínica. Cir Ciruj. 2009;77:417-9.

2. Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of hepatocellular carcinoma incidence in the United States forecast through 2030. J Clin Oncol. 2016;34(15):1787-94.

3. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835-53.

4. Heimbach JK, Kulik LM, Finn R, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology. 2017 Jan 28.

5. González Huezo M, Sánchez Ávila J. Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular. Rev Gastroenterol Mex. 2014;79(4):250-62.

6. Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, et al. Survival rate in patients with hepatocellular carcinoma: A retrospective analysis of 389 patients. Br J Cancer. 2005;92:1862-8.

7. Méndez-Sánchez N, Aguilar-Ramírez JR, Reyes A, Dehesa M, Juárez A, Castañeda B, et al.; Grupo de Estudio, Asociación Mexicana de Hepatología. Etiology of liver cirrhosis in Mexico, Ann Hepatol. 2004;3(1):30-3.

8. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013;108:1314-21.

9. Younossi ZM, Koening AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.

10. Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):124-31.

11. Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67(1):6-19.

12. Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med. 2012;156:387-9.

13. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, et al. Screening for liver cancer: results of a randomized controlled trial in Qidong, China. J Med Screen. 2003;10:204-9.

14. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-22.

15. Waidely E, Al-Yuobi AR, Bashammakh AS, El-Shahawi MS, Leblanc RM. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst. 2016;141(1):36-44.

16. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835-53.

17. Hepatobiliary Cancers [Internet]. National Comprehensive Cancer Network [Fecha publicación: abril 2017]. Disponible en: https://www.nccn. org/professionals/physician_gls/pdf/hepatobiliary.pdf

18. Erazo-Valle A, Escudero P, Sotelo J, Barrera JL, Benítez H, Cabrera PA, et al. Guía mexicana de tratamiento del hepatocarcinoma avanzado. GAMO. 2012;11(Supl 2):3-14.

19. Khalili K, Kim TK, Jang HJ, Yazdi LK, Guindi M, Sherman M. Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance: biopsy for all, some, or none? Hepatology. 2011;54(6):2048-54.

20. Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, et al. Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. Med Clin (Barc). 2016;146(11):511.

21. Park YN. Update on precursor and early lesions of hepatocellular carcinomas. Arch Pathol Lab Med. 2011;135(6):704-15.

22. González Huezo S, Sánchez Ávila J. Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular. Rev Gastroenterol Méx. 2014;79(4):250-62.

23. Gómez Senent S, Gómez Raposo C, Segura Cabral JM. Updated guide for diagnosis, staging and treatment of hepatocellular carcinoma. Med Clin (Barc). 2007;128(19):741-8.

24. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-38.

25. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-55.

26. Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014;11:525-35.

27. Koneru B, Teperman LW, Manzarbeitia C, Facciuto M, Cho K, Reich D, et al. A multicenter evaluation of utility of chest computed tomography and bone scans in liver transplant candidates with stages I and II hepatoma. Ann Surg. 2005;241:622-8.

28. Rodríguez S, Balbinotto Neto G, Kiss G, Brandão A; Liver Transplantation Group. Cost-effectiveness of whole-body bone scans in the pre-liver transplant assessment of patients with hepatocellular carcinoma in Southern Brazil. Clin Transplant. 2016;30:399-406.

29. Akamatsu N, Cillo U, Cucchetti A, Donadon M, Pinna AD, Torzilli G, et al. Surgery and hepatocellular carcinoma. Liver Cancer. 2017;6:44-50.

30. Sposito C, Di Sandro S, Brunero F, Buscemi V, Battiston C, Lauterio A, et al. Development of a prognostic scoring system for resectable hepatocellular carcinoma. World J Gastroenterol. 2016;22:8194-202.

31. Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G, et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg. 2009;250:922-8.

32. Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, et al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? an observational study of the HCC East-West study group. Ann Surg. 2013;257:929-37.

33. Roayaie S, Jibara G, Taouli B, Schwartz M. Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol. 2013;20:3754-60.

34. Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology. 2015;62:440-51.

35. Tan Y, Zhang W, Jiang L, Yang J, Yan L. Efficacy and safety of anatomic resection versus nonanatomic resection in patients with hepatocellular carcinoma: A systemic review and meta-analysis. PLoS One. 2017;12(10):e0186930.

36. Liu PH, Hsu CY, Hsia CY, Lee YH, Huang YH, Chiou YY, et al. Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma ≤ 2 cm in a propensity score model. Ann Surg. 2016;263:538-45.

37. Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 2010;10:78.

38. Ettorre GM, Levi Sandri GB, Colasanti M, Mascianà G, de Werra E, Santoro R, et al. Liver resection for hepatocellular carcinoma ≥5 cm. Transl Gastroenterol Hepatol. 2017;2:22-7.

39. Mazzaferro V. Results of liver transplantation: with or without Milan criteria? Liver Transpl. 2007;11(Suppl 2):S44-47.

40. Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008;4:1001-7.

41. Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, et al. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl. 2011;17(Suppl 2):S81-9.

42. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-403.

43. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A; OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11-22.

44. Kamo N, Kaido T, Yagi S, Okajima H, Uemoto S. Liver transplantation for small hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2016;5:391-8.

45. Lin CC, Chen CL. Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes. Hepatobiliary Surg Nutr. 2016;5:415-21.

46. Coskun M. Hepatocellular carcinoma in the cirrhotic liver: Evaluation using computed tomography and magnetic resonance imaging. Exp Clin Transplant. 2017;15(Suppl 2):36-44.

47. Majno P, Mentha G, Mazzaferro V. Resection, transplantation, either, or both? Other pieces of the puzzle. Liver Transpl. 2005;11:1177-80.

48. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-9.

49. Lee KW, Yi NJ, Suh KS. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience. Transplantation. 2014;97(Suppl 8):S20-3.

50. Menahem B, Lubrano J, Duvoux C, Mulliri A, Alves A, Costentin C, et al. Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis. Liver Transpl. 2017;23:836-44.

51. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348-59.

52. Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma. Adv Ther. 2016;33(5):699-714.

53. Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities, Int J Radiat Oncol Biol Phys. 2013;87(1):22-32.

54. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al.; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting- bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study, Cardiovasc Intervent Radiol. 2010;33(1):41-52.

55. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60.

56. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57(5):1826-37.

57. Park HC, Yu J, Cheng JC, Zeng ZC, Hong JH, Wang ML, et al. Consensus for radiotherapy in hepatocellular carcinoma from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current practice and future clinical trials. Liver Cancer. 2016;5(3):162-74.

58. Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl. 2015;21(9):1142-52.

59. Yu CY, Ou HY, Huang TL, Chen TY, Tsang LL, Chen CL, et al. Hepatocellular carcinoma downstaging in liver transplantation. Transplant Proc. 2012;c44(2):412-14.

60. Sanjeeva P, Iqbal SI, Yeddula K, Blaszkowsky LS, Akbar A, Wicky S. Transarterial chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. Gastrointest Cancer Res. 2011;4(1):2-8.

61. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348-59.

62. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-90.

63. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafenib): second interim analysis. Int J Clin Pract. 2014;68(5):609-17.

64. Bruix J, Quin S, Merle P. Regorafenib for patients with heapatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56-66.

65. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (Check- Mate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492-502.

66. Grothey A, van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo- controlled, phase 3 trial. Lancet. 2013;381(9863):303-12.

67. Rimassa L, Pressiani T, Personeni N, Santoro A. Regorafenib for the treatment of unresectable hepatocellular carcinoma. Expert Rev Anticancer Ther. 2017;17(7):567-76.

68. Trojan J, Waidmann O. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2016;3:31-6.

69. Kondo M, Numata K, Hara K, Nozaki A, Fukuda H, Chuma M, et al. Treatment of advanced hepatocellular carcinoma after failure of sorafenib treatment: subsequent or additional treatment interventions contribute to prolonged survival postprogression. Gastroenterol Res Pract. 2017;2017:5728946.

70. Kudo M. Regorafenib as second-line systemic therapy may change the treatment strategy and management paradigm for hepatocellular carcinoma. Liver Cancer. 2016;5(4):235-44.

71. Frenette C. The role of regorafenib in hepatocellular carcinoma. Gastroenterol Hepatol. 2017;13(2):122- 4.